The Design of a Drug-Eluting Stent System

Boston Scientific

The Challenges of the SFA

Boston Scientific

Dr. Lookstein IMPERIAL 2-Year Data

Boston Scientific

R. Lookstein

Drug-Eluting Stents: The Challenge

Boston Scientific

L. Garcia, M. Jaff, R. Lookstein

IMPERIAL Trial: First of its Kind Design

Boston Scientific

W. Gray, R. Lookstein, M. Jaff

IMPERIAL Trial: Influencing Treatment Algorithms

Boston Scientific

S. Henao, M. Jaff, W. Gray, R. Lookstein, G. Ansel

Drug-Eluting Stents: The Solution

Boston Scientific

J. Granada, M. Montero-Baker, A. Holden, G. Ansel

Drug-Eluting Stents: The Breakthrough

Boston Scientific

A. Holden, W. Gray, R. Lookstein, T. Zeller

Impact of the IMPERIAL Trial

Boston Scientific

M. Jaff, W. Gray, R. Lookstein, S. Henao, G. Ansel

Drug-Eluting Stents: The Heritage

Boston Scientific

G. Ansel, M. Jaff, R. Lookstein, J. Diaz-Cartelle

Bioresorbable Technology in Below-the-Knee Intervention

NY Endovascular Summit

S. Parikh

Boston Scientific Drug-Eluting Technologies

Boston Scientific

R. Sachar

Drug-Eluting Stents: The Data

Boston Scientific

J. Diaz-Cartelle, R. Lookstein, L. Garcia

Below the Knee Therapies: State of the Art

ARCH Advanced Revascularization Symposium

V. Kapur

Subacute Occlusion Left SFA - Leipzig, Germany - LINC 2019

NY Endovascular Summit

A. Schmidt

Clinical Update in Drug Eluting Technologies for PAD

Boston Scientific

P. Monteleone

Drug-Eluting Technology for Below-the-Knee Intervention

NY Endovascular Summit

M. Bunte

Treatment of Femoral-Popliteal Disease: What Are the Factors that Ne…

ARCH Advanced Revascularization Symposium

A. Thomas

Paclitaxel or Limus: What Is the Future in Drug Eluting Therapies?

ARCH Advanced Revascularization Symposium

C. Walker

What Stent to Use 2019

ARCH Advanced Revascularization Symposium

J. Singh